Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: Comparison with heparin

1 The antithrombotic action of argatroban, a synthetic thrombin inhibitor, was studied in a canine model of coronary cyclic flow having some of the characteristics of acute unstable angina. Heparin was studied as a reference anticoagulant. 2 Localized endothelial damage was induced in the circumflex coronary artery of anaesthetized open-chest foxhounds and a critical stenosis was applied by use of a Lexan constrictor placed around the artery at the site of endothelial damage. An electro-magnetic flow probe was placed distal to the lesion, and cyclic flow variations (CFVs) were observed, as thrombi formed at the site of the arterial lesion and were dislodged. Test compounds were administered by i.v. infusion commencing 1 h after the appearance of CFVs, and maintained for 1 h. On termination of the treatments, coronary flow was observed for a further 60 min. A series of blood samples were taken at predetermined times throughout each experiment in order to determine the coagulation parameters, thrombin time (TT) activated partial thromboplastin time (aPTT) and for the determination of fibrinopeptide A (FpA) levels before, during and posttreatment. 3 Argatroban and heparin showed antithrombotic effects in this model. Argatroban dose-dependently increased the minimum coronary flow at the nadir of the CFVs from 5.4+/-1.7 to 9.1+/-2.1 ml min(-1) (30 mu g kg(-1) min(-1), P=0.041) and from 2.9+/-0.9 to 16.3+/-4.5 ml min(-1) (100 mu g kg(-1) min(-1), P=0.023, n=8 dogs at each dose level). Heparin (5 and 15 iu kg(-1) min(-1)) also increased minimum flow, but the increase was not statistically significant at the 5% level, although the P Value in animals treated with 15 iu kg(-1) min(-1) (P=0.0521, n=6 dogs) fell just outside this limit. Although neither compound significantly decreased the overall CFV frequency, argatroban (100 mu g kg(-1) min(-1)) significantly (P<0.01) decreased the number of large amplitude CFVs (minimum coronary flow<10 ml min(-1)) by 63%, and heparin (15 iu kg(-1) min(-1)) caused a 50% decrease in this parameter (P<0.05). 4 The thrombin times were increased by a factor greater than 10 during antithrombotic treatment, irrespective of the compound or doses used. Heparin treatment induced 17 and >30 fold increases in aPTT at 5 and 15 iu kg(-1) min(-1) respectively. However, argatroban produced only 2 and 3 fold increases in aPTT at 30 and 100 pg kg(-1) min(-1), despite significant antithrombotic effects. FpA levels were reduced in the presence of both argatroban and heparin. 5 These data show that, when administered as an intravenous infusion, argatroban is a potent antithrombotic agent in a canine model of coronary cyclic flow.